Market Place
Sourcing Support
Clene Reports Q3 2024 Results & Operating Highlights
13 Nov 2024 //
GLOBENEWSWIRE
Clene to Present at Upcoming October Conferences
09 Oct 2024 //
GLOBENEWSWIRE
Clene Closes $7.3M Direct Offering and Debt Facility Amendment
01 Oct 2024 //
GLOBENEWSWIRE
Clene Granted FDA Meeting To Discuss CNM-Au8 Data
16 Sep 2024 //
GLOBENEWSWIRE
Clene Reports Q2 2024 Financial Results And Operating Highlights
07 Aug 2024 //
GLOBENEWSWIRE
Clene Submits New CNM-Au8® Data To FDA For ALS Treatment
06 Aug 2024 //
GLOBENEWSWIRE
Clene To Present At Canaccord Genuity Growth Conference
05 Aug 2024 //
GLOBENEWSWIRE
Clene to Present at the Emerging Growth Conference
12 Jul 2024 //
GLOBENEWSWIRE
Clene To Submit FDA Briefing For CNM-Au8® Accelerated Approval In ALS
11 Jul 2024 //
GLOBENEWSWIRE
Clene Announces 1-for-20 Reverse Stock Split
09 Jul 2024 //
GLOBENEWSWIRE
Clene to Present at H.C. Wainwright`s Neuro Perspectives Virtual Conference
24 Jun 2024 //
GLOBENEWSWIRE
Clene Presents Preliminary Data for CNM-Au8® in Rett Syndrome
21 Jun 2024 //
GLOBENEWSWIRE
Clene Presents Extended Survival Data For CNM-Au8® At ENCALS Meeting
18 Jun 2024 //
GLOBENEWSWIRE
Clene to Present at the Emerging Growth Conference
05 Jun 2024 //
GLOBENEWSWIRE
Clene: Update On NIH-Funded CNM-Au8 ALS Expanded Access Program
28 May 2024 //
GLOBENEWSWIRE
Clene to Present at Upcoming May Conferences
14 May 2024 //
GLOBENEWSWIRE
Clene Q1 2024 Financials, Operating Highlights
08 May 2024 //
GLOBENEWSWIRE
Clene`s CNM-Au8® Data Presented at American Academy of Neurology Meeting
16 Apr 2024 //
GLOBENEWSWIRE
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment
29 Feb 2024 //
GLOBENEWSWIRE
FDA Denies Accelerated Approval for Clene’s ALS Candidate
22 Dec 2023 //
BIOSPACE
Clene Provides Update on ALS Clinical Development Meeting With FDA
21 Dec 2023 //
GLOBENEWSWIRE
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels
21 Dec 2023 //
GLOBENEWSWIRE
Clene Announces Publication Describing CNM-Au8 Brain Target Engagement
14 Dec 2023 //
GLOBENEWSWIRE
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
07 Nov 2023 //
GLOBENEWSWIRE
Clene Announces Peer-Reviewed Publication Describing CNM-Au8
28 Sep 2023 //
GLOBENEWSWIRE
Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
25 Sep 2023 //
GLOBENEWSWIRE
Clene Reports Survival Improvement From CNM-Au8 Treatment in ALS Platform Trial
25 Sep 2023 //
GLOBENEWSWIRE
Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
14 Aug 2023 //
GLOBENEWSWIRE
Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
02 Aug 2023 //
GLOBENEWSWIRE
Clene Announces Publication of Phase 2 CNM-Au8® Data for the Treatment of ALS
26 Jun 2023 //
GLOBENEWSWIRE
Clene claims ALS therapy hits biomarker behind Qalsody approval
16 Jun 2023 //
FIERCE BIOTECH
Clene to Participate in the Maxim Group Virtual Healthcare Conference
15 Jun 2023 //
GLOBENEWSWIRE
Clene™s CNM-Au8® Shows Statistically Significant Difference in (NfL) levels
15 Jun 2023 //
GLOBENEWSWIRE
Clene Announces Launch of Proposed Public Offering
15 Jun 2023 //
GLOBENEWSWIRE
Clene`s ALS drug shows reduction in disease indicator levels in trial
15 Jun 2023 //
REUTERS
Clene Awarded Grant From National Multiple Sclerosis Society
25 May 2023 //
GLOBENEWSWIRE
Clene Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
Clene Announces Presentations of MS & ALS Data Supporting Efficacy of CNM-Au8
11 Apr 2023 //
GLOBENEWSWIRE
Clene Appoints Neurology Expert to Executive Team
16 Mar 2023 //
GLOBENEWSWIRE
Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights
13 Mar 2023 //
GLOBENEWSWIRE
Clene Nanomedicine to Participate in Roth 35th Annual Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
New Data Show CNM-Au8 Preserved ALS Patient Function
06 Mar 2023 //
GLOBENEWSWIRE
Clene Announces Updated VISIONARY-MS PII Data Presented at 2023 ACTRIMS
27 Feb 2023 //
GLOBENEWSWIRE
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis
13 Feb 2023 //
GLOBENEWSWIRE
Clene Announces Participation in Renmark Virtual Non-Deal Roadshow Series
11 Jan 2023 //
GLOBENEWSWIRE
Clene Nanomedicine Reports Topline Results of Ph 2 COVID-19 Study of CNM-ZnAg
27 Dec 2022 //
GLOBENEWSWIRE
Clene Reports 3Q 2022 Financial Results and Recent Operating Highlights
07 Nov 2022 //
GLOBENEWSWIRE
Clene Announces $10.8M Registered Direct Offering and $5M Debt Facility
31 Oct 2022 //
GLOBENEWSWIRE
Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS
21 Sep 2022 //
GLOBENEWSWIRE
Clene claims MS drug win, but data leaves questions
15 Aug 2022 //
FIERCEBIOTECH
Clene Receives Positive EMA Opinion on OrDD for CNM-Au8 for ALS
19 Jul 2022 //
GLOBENEWSWIRE
Dark-horse ALS player touts open-label survival data after mid-stage flop
14 Jul 2022 //
ENDPTS
Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Trial
14 Jul 2022 //
GLOBENEWSWIRE
Clene to Participate in Panel Discussion About Innovations in ALS
27 Jun 2022 //
GLOBENEWSWIRE
Maryland offers loan to Clene despite ALS trial bumps
19 May 2022 //
ENDPTS
ALS: Clene plans 300-patient Phase III trial of CNM-Au8
14 Apr 2022 //
CLINICALTRIALSARENA
Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session
10 Dec 2021 //
GLOBENEWSWIRE
Clene Nanomedicine’s RESCUE-ALS Phase 2 Results Selected for Late-Breaking
07 Dec 2021 //
GLOBENEWSWIRE
Clene Nanomedicine Announces Top-Line Results from Phase 2
02 Nov 2021 //
BIOSPACE
